Organization
Oblato
5 clinical trials
Clinical trial
A Phase 1b Open-Label Study Investigating the Tolerability, Safety, and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade GliomaStatus: Recruiting, Estimated PCD: 2024-05-15
Clinical trial
Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-alteredStatus:
Clinical trial
A Phase II Open-label Study Investigating the Efficacy, Safety and Pharmacokinetic Properties of OKN-007 Combined With Temozolomide in Patients With Recurrent GlioblastomaStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Phase 1b Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma PatientsStatus: Active (not recruiting), Estimated PCD: 2023-01-31
Clinical trial
A Phase Ib/2 Open-label Study Investigating the Tolerability, Safety, Pharmacokinetic Properties and Efficacy of Oral OKN-007 in Participants With Recurrent High-grade GliomaStatus: Withdrawn, Estimated PCD: 2025-04-01